Guanidine-Dextran Conjugates for Tumor Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antitumor drugs often have significant toxic effects and side effects, limiting their efficacy and tolerability in cancer treatment.
Innovation Solution
A modified hydroxypolymer conjugate, specifically a guanidine-dextran conjugate, is developed by covalently coupling guanidine compounds like agmatine or aminoguanidine to a dextran polymer, creating a compound with high tumor cell killing efficacy similar or superior to established anticancer drugs like Adriamycin, while maintaining low intrinsic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antitumor drugs are used to achieve high tumor cell killing efficacy, then the antitumor effect is improved, but the toxic effects and side effects increase significantly
Solution Approach 1:
The patent creates a composite material by covalently coupling guanidine compounds (agmatine or aminoguanidine) to a dextran polymer backbone. This composite structure combines the antitumor activity of guanidine compounds with the biocompatibility and low toxicity of dextran, achieving high tumor cell killing efficacy while significantly reducing toxic effects and side effects compared to conventional antitumor drugs
Solution Approach 2:
The patent modifies the chemical structure by changing the substitution degree of guanidine compounds on the dextran polymer (15-60% substitution). This parameter optimization allows tuning of the conjugate's biological activity and pharmacokinetic properties, achieving maximum antitumor efficacy with minimized toxicity
2Reliability
If guanidine compounds are covalently conjugated to activated hydroxypolymer then the antitumor efficacy is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent employs preliminary activation of the dextran polymer with periodate to generate aldehyde groups before coupling with guanidine compounds. This pre-activation step simplifies the overall conjugation process by creating reactive sites that readily react with amino groups of guanidine compounds, making the manufacturing process more controllable and reproducible
Solution Approach 2:
The patent uses periodate-activated dextran as an intermediary structure that facilitates the coupling reaction between the polymer backbone and guanidine compounds. The aldehyde groups generated by periodate activation serve as reactive intermediaries that form stable covalent bonds with amino groups, simplifying the conjugation process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The guanidine-dextran conjugate demonstrates high antitumor efficacy with reduced toxicity, potentially offering favorable handling and side-effect profiles for medical staff and patients, and can be administered via various routes, including local, systemic, or intratumoral injection.
Implementation Method 1
The hydroxypolymer is activated by an oxidative reaction, wherein a periodate salt is added to an aqueous solution comprising said hydroxypolymer
Implementation Method 2
guanidine compounds, which are covalently coupled to activated hydroxyl groups of the hydroxypolymer moiety
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is related to a modified hydroxypolymer conjugate, preferably a guanidine-dextran conjugate having a tumor cell killing activity. The modified hydroxypolymer conjugate is used as medicine, particularly for manufacturing a medicine or tumor killing composition for treating tumors. A method for producing said hydroxypolymer conjugate is also disclosed.